Oppenheimer Holdings, Inc. Reaffirms Outperform Rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)‘s stock had its “outperform” rating restated by analysts at Oppenheimer Holdings, Inc. in a research report issued on Thursday. They currently have a $83.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $75.00. Oppenheimer Holdings, Inc.’s target price would indicate a potential upside of 37.05% from the company’s current price. Oppenheimer Holdings also issued estimates for Agios Pharmaceuticals’ Q3 2017 earnings at ($1.99) EPS, Q4 2017 earnings at ($2.04) EPS, Q1 2018 earnings at ($2.31) EPS, Q2 2018 earnings at ($2.31) EPS, Q3 2018 earnings at ($2.45) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($7.28) EPS, FY2019 earnings at ($1.43) EPS and FY2020 earnings at $3.10 EPS.
Several other brokerages also recently commented on AGIO. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Needham & Company LLC boosted their price objective on Agios Pharmaceuticals from $54.00 to $72.00 and gave the company a “buy” rating in a research report on Thursday. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday. BidaskClub downgraded Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, Janney Montgomery Scott downgraded Agios Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, June 26th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $71.56.
Shares of Agios Pharmaceuticals (NASDAQ AGIO) traded down 1.35% on Thursday, hitting $59.74. The stock had a trading volume of 39,384 shares. Agios Pharmaceuticals has a 12 month low of $35.84 and a 12 month high of $67.74. The stock’s market cap is $2.88 billion. The stock has a 50 day moving average of $56.81 and a 200-day moving average of $51.69.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 75.48%. The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $10.68 million. During the same quarter in the previous year, the firm earned ($1.47) earnings per share. Agios Pharmaceuticals’s revenue was up 62.1% on a year-over-year basis. Equities research analysts anticipate that Agios Pharmaceuticals will post ($6.90) EPS for the current year.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total transaction of $150,060.00. Following the sale, the chief executive officer now directly owns 1,100 shares of the company’s stock, valued at $55,022. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $50.87, for a total value of $101,740.00. Following the sale, the director now directly owns 90,197 shares in the company, valued at $4,588,321.39. The disclosure for this sale can be found here. Insiders have sold 79,120 shares of company stock worth $4,557,207 over the last three months. 10.55% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of AGIO. First Trust Advisors LP boosted its stake in shares of Agios Pharmaceuticals by 17.8% in the first quarter. First Trust Advisors LP now owns 639,579 shares of the biopharmaceutical company’s stock valued at $37,351,000 after buying an additional 96,712 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Agios Pharmaceuticals by 0.3% in the first quarter. State Board of Administration of Florida Retirement System now owns 39,473 shares of the biopharmaceutical company’s stock valued at $2,305,000 after buying an additional 126 shares during the period. C WorldWide Group Holding A S acquired a new position in shares of Agios Pharmaceuticals during the first quarter valued at about $105,000. Canada Pension Plan Investment Board raised its position in shares of Agios Pharmaceuticals by 152.1% in the first quarter. Canada Pension Plan Investment Board now owns 30,500 shares of the biopharmaceutical company’s stock valued at $1,781,000 after buying an additional 18,400 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Agios Pharmaceuticals by 312.0% in the first quarter. Wells Fargo & Company MN now owns 40,084 shares of the biopharmaceutical company’s stock valued at $2,341,000 after buying an additional 30,354 shares during the period. 84.53% of the stock is currently owned by institutional investors.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.